In the fight against leukemia and lymphoma, T cells are a powerful tool. But T cell therapies are notoriously fraught with challenges that can be difficult to overcome. We introduce CDR3’s unique, patented technology that creates a permanent, self-renewing source of T cells directed against diseased cells over the lifetime of a patient. It connects a much-needed therapy to the lives of people who need it. And while we can make this revolutionary new cancer treatment, we need to make the treatment possible. Through your investment in CDR3, you’ll see pain begin to disappear, lives start to improve, and your portfolio produce a return – all while helping humanity in a positive new direction.
Company Details
- Founded
- 2017
- Address
- Los Angeles, Ca 90095, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.cdr3therapeutics.com
- Keywords
- immunotherapy, stem cells, CARs, chimeric antigen receptors, TCRs, virus-associated cancer, HSPCs, chronic viral infections.
- HQ
- Los Angeles, CA
Cdr3 Therapeutics Questions
Cdr3 Therapeutics's website is http://www.cdr3therapeutics.com
Cdr3 Therapeutics's LinkedIn profile is https://www.linkedin.com/company/cdr3-therapeutics
Cdr3 Therapeutics's industry is
Biotechnology Research
Cdr3 Therapeutics's top competitors are
Puma Biotechnology, Inc.,
Femcap Inc.,
Sandiegomics,
Avenzoar,
Pelage Pharmaceuticals,
Immunovision, Inc.,
Centro De Economía Del Conocimiento E Innovación (Ceci San Juan),
Ucla Ventures,
Axxin,
Neuroindx, Inc..
Cdr3 Therapeutics's categories are Biotechnology Research
Cdr3 Therapeutics's founding year is 2017
